The deal-making furor surrounding Toll-like receptors (TLRs) is continuing, with Merck KGaA agreeing to pay up to $421 million for worldwide rights in cancer indications to Idera Pharmaceuticals Inc.'s for TLR9 agonists. (BioWorld Today)